D1 Capital Partners has led a $102m series D round for Inflammatix, whose existing shareholders include Stanford-StartX Fund.

Inflammatix, a US-based molecular diagnostics company based on research at Stanford University, closed a $102m series D round yesterday led by D1 Capital Partners. OSF Healthcare Ventures, the investment arm of health system OSF Healthcare, also took part in the round, as did Northpond Ventures, Khosla Ventures and Think.Health. Founded in 2016, Inflammatix is working…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.